EGFR and non-small cell lung carcinoma: The NCCN Panel's 2022 update (Version 1) recommends afatinib or Osimertinib as preferred first-line therapies for metastatic NSCLC with specific EGFR mutations, such as S768I, L861Q, and G719X (25).